secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001854270-25-000062
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio reports Q1 2025 net loss $14.1M; SENTI-202 Phase 1 shows 4 of 7 cCR with MRD negativity
--------------------------------------------------------------------------------

- Net loss of $14.1M ($1.41 per share) for Q1 2025; cash and equivalents $33.8M as of March 31.
- Phase 1 SENTI-202 data: 4 of 7 patients achieved composite CR (3 CR, 1 CRh); all MRD negative by local standard of care.
- Preliminary RP2D set at 1.5 x 10^9 CAR NK cells given on Days 0,7,14 in 28-day cycles after lymphodepletion.
- Responses ongoing from 4+ to 8+ months; 3 patients received bone marrow transplant after SENTI-202.
- R&D expenses $9.3M (up $0.5M YoY); G&A expenses $7.1M (down $0.4M YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427025000062/0001854270-25-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427025000062/snti-20250506.htm
  HTML page:      https://secwatch.observer/filing/0001854270-25-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer